Richard Aplenc, MD, PhD, MSCE
Dr. Richard Aplenc is a core faculty member of the Center for Pediatric Clinical Effectiveness (CPCE) and an attending physician in the Division of Oncology at Children’s Hospital of Philadelphia (CHOP), and Chief Clinical Research Officer at the CHOP Research Institute. He is also a professor in the Department of Pediatrics with a secondary appointment in the Department of Biostatistics, Informatics, and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania.
Dr. Aplenc’s research focuses on pediatric acute myeloid leukemia (AML) with ongoing clinical epidemiology and translational research projects. His work involves the treatment of AML in children and the use of genetic data to predict treatment response to therapeutic interventions.
His clinical epidemiology research focuses on improving adverse event reporting on clinical trials in the Children's Oncology Group (COG) by merging external data sets to COG clinical trial data. He is also leveraging data set merging for clinical epidemiology investigations in pediatric AML with a particular focus on cardio-oncology and disparities in treatment outcome. He leads a PCORI research effort to study medical and patient reported outcomes with various discharge practices after AML chemotherapy administration.
From a translational standpoint, he leads efforts to identify risk alleles for pediatric AML susceptibility and treatment response with genome-wide genotyping and next generation sequencing. He also leads a Hyundai Quantum Award to characterize the AML blast cell surfaceome. Finally, he led the recently completed Phase III trial for children with AML in the Children's Oncology Group (COG) and serves as the Vice-Chair of the COG Strategy AML Committee.
Contact Dr. Aplenc at email@example.com.